Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, is enhancing its supply chain strategy with artificial intelligence-based technologies provided by Bluecrux, a consulting and technology firm based in Belgium. Bluecrux’s solution consolidates all of Sanofi’s data systems into a unified model, enabling comprehensive end-to-end visibility across the company’s supply chain. This integration aims to identify areas for optimization and enhance overall efficiency.
As reported by rencent public data, earlier this month, Sanofi collaborated with Formation Bio and OpenAI to expedite drug development. These partnerships are part of Sanofi’s broader initiative to implement AI on a large scale across its operations.- Flcube.com
